Xponance Inc. Sells 822 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Xponance Inc. cut its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 2.0% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 40,060 shares of the medical research company’s stock after selling 822 shares during the period. Xponance Inc.’s holdings in IQVIA were worth $9,269,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Parkside Financial Bank & Trust raised its position in IQVIA by 19.6% during the 2nd quarter. Parkside Financial Bank & Trust now owns 293 shares of the medical research company’s stock valued at $66,000 after purchasing an additional 48 shares in the last quarter. Laurel Wealth Advisors LLC grew its stake in IQVIA by 1.1% during the 3rd quarter. Laurel Wealth Advisors LLC now owns 4,710 shares of the medical research company’s stock worth $927,000 after buying an additional 50 shares during the last quarter. Private Advisor Group LLC grew its stake in IQVIA by 1.2% during the 3rd quarter. Private Advisor Group LLC now owns 4,818 shares of the medical research company’s stock worth $948,000 after buying an additional 56 shares during the last quarter. B. Riley Wealth Advisors Inc. grew its stake in IQVIA by 1.6% during the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 3,568 shares of the medical research company’s stock worth $702,000 after buying an additional 56 shares during the last quarter. Finally, Penserra Capital Management LLC grew its stake in IQVIA by 6.1% during the 4th quarter. Penserra Capital Management LLC now owns 971 shares of the medical research company’s stock valued at $198,000 after purchasing an additional 56 shares during the last quarter. 89.62% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

IQV has been the topic of several research analyst reports. Guggenheim downgraded IQVIA from a “buy” rating to a “neutral” rating in a research note on Thursday, February 15th. Barclays boosted their price objective on IQVIA from $260.00 to $265.00 and gave the company an “overweight” rating in a report on Thursday, February 15th. SVB Leerink started coverage on IQVIA in a report on Monday, February 26th. They issued an “outperform” rating and a $290.00 price objective for the company. UBS Group upped their price target on IQVIA from $240.00 to $300.00 and gave the stock a “buy” rating in a report on Thursday, February 15th. Finally, Evercore ISI upped their price target on IQVIA from $255.00 to $265.00 and gave the stock a “market outperform” rating in a report on Thursday, February 15th. Three research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat.com, IQVIA currently has an average rating of “Moderate Buy” and an average target price of $256.80.

IQVIA Price Performance

Shares of NYSE:IQV traded up $1.67 during midday trading on Friday, hitting $228.84. The company had a trading volume of 51,774 shares, compared to its average volume of 957,007. IQVIA Holdings Inc. has a twelve month low of $167.42 and a twelve month high of $261.73. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.86 and a quick ratio of 0.86. The stock has a market cap of $41.53 billion, a price-to-earnings ratio of 31.16, a price-to-earnings-growth ratio of 2.20 and a beta of 1.50. The business’s 50-day simple moving average is $244.62 and its 200-day simple moving average is $221.41.

IQVIA (NYSE:IQV) last posted its earnings results on Wednesday, February 14th. The medical research company reported $2.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.82 by $0.02. IQVIA had a return on equity of 29.32% and a net margin of 9.06%. The company had revenue of $3.87 billion during the quarter, compared to analysts’ expectations of $3.80 billion. During the same quarter last year, the firm earned $2.54 earnings per share. The firm’s quarterly revenue was up 3.5% compared to the same quarter last year. On average, research analysts predict that IQVIA Holdings Inc. will post 10.11 earnings per share for the current year.

Insider Activity

In other news, insider Eric Sherbet sold 1,000 shares of IQVIA stock in a transaction on Friday, February 16th. The stock was sold at an average price of $241.50, for a total value of $241,500.00. Following the completion of the sale, the insider now directly owns 20,836 shares of the company’s stock, valued at $5,031,894. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, insider Ari Bousbib sold 31,678 shares of IQVIA stock in a transaction on Friday, March 1st. The stock was sold at an average price of $250.53, for a total value of $7,936,289.34. Following the completion of the transaction, the insider now directly owns 796,752 shares in the company, valued at $199,610,278.56. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Eric Sherbet sold 1,000 shares of IQVIA stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $241.50, for a total value of $241,500.00. Following the sale, the insider now directly owns 20,836 shares of the company’s stock, valued at $5,031,894. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 41,285 shares of company stock valued at $10,331,003. 1.60% of the stock is currently owned by corporate insiders.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.